Gerda M. Verduijn

Erasmus MC Cancer Institute

Papers

1

Total Citations

6

H-Index

1

About

Gerda M. Verduijn is a leading clinical researcher in radiation oncology, with a focused expertise in breast cancer treatment and the mitigation of radiation-induced toxicities. Her work is central to improving the quality of life for patients undergoing accelerated partial breast irradiation (APBI). Her most notable contribution is the design and execution of a randomized controlled trial investigating the use of a hyaluronic acid spacer injection to reduce skin toxicity during brachytherapy APBI. This study protocol, published in 2018, addresses a critical clinical problem: the skin dose as a primary risk factor for adverse effects. By proposing a pre-treatment injection to physically separate the skin from the target volume, Verduijn’s research pioneers a proactive, non-surgical method to minimize burns and fibrosis. While her most cited paper has garnered 6 citations, its impact is significant as a foundational protocol for a novel intervention. This work positions Verduijn at the forefront of patient-centered radiation oncology, where the goal is not just tumor control, but the preservation of healthy tissue and cosmetic outcomes. Her research is a vital resource for clinicians seeking to refine APBI techniques and for students interested in translational research that directly improves clinical practice.

Research Focus

Key Achievements

1
H-Index
1
Papers
6
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
A randomized controlled trial testing a hyaluronic acid spacer injection for skin toxicity reduction of brachytherapy accelerated partial breast irradiation (APBI): a study protocol
6 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: Erasmus MC Cancer Institute

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago